INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
MWN-AI** Summary
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology, has announced two significant presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego, CA, taking place from December 1-4, 2025.
The first presentation, titled "XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial," will be delivered by Dr. Kim A. Staats on December 1-2. This research focuses on the effects of XPro1595, a selective neutralizer of soluble tumor necrosis factor (TNF), known for its role in driving innate immune dysfunction in various diseases, including Alzheimer’s.
The second presentation, scheduled for December 4, features Dr. Sarah Barnum discussing the "Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease." This research aims to validate critical cognitive assessments associated with Alzheimer’s disease biomarkers, enhancing diagnostic capabilities.
INmune Bio’s product platforms focus on innovative strategies to tackle immunology and inflammation-related conditions. Their leading technology, the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, aims at targeting soluble TNF to address immune dysfunction. Other platforms include CORDStrom™, utilizing human umbilical cord-derived mesenchymal stem cells for various trials, and INKmune®, designed to enhance natural killer cell activity in cancer patients.
While INmune Bio's advancements are promising, it acknowledges that clinical trials are in early stages and uncertainties remain regarding product development, regulatory approval, and commercialization. The company will continue to monitor and disclose relevant updates as they progress in their journey toward potential breakthroughs in Alzheimer’s treatment and other conditions. For more information, please visit www.inmunebio.com.
MWN-AI** Analysis
**Market Analysis and Investment Advice on INmune Bio (NASDAQ: INMB)**
As INmune Bio prepares for its two upcoming presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference, investor attention is likely to intensify around the stock. The focus will be on the Phase 2 MINDFuL trial of XPro1595, which targets inflammation in early Alzheimer’s patients. Given the urgent need for effective Alzheimer's treatments, positive data from this trial could significantly boost market confidence in INMB.
However, potential investors should remain cautious. Clinical-stage biotech firms often experience volatility based on trial results announcements. The focus on early trial results implies that while potential rewards are substantial, the risks are equally significant due to the unpredictability of clinical outcomes and regulatory approvals. Historical data suggests that many trials fail to meet endpoints, leading to stock price drops.
Additionally, INmune’s diverse product platforms—ranging from the DN-TNF platform to its cord-derived Stromal cell therapies—provide a buffer against risk, but they also necessitate substantial funding for ongoing trials. As noted in the press release, financial sustainability remains a key concern; investors should monitor INmune’s funding situation closely, particularly in the context of potential dilution or capital raises.
For short-term traders, strategizing around the conference might present opportunities; a favorable trial outcome might spike the stock price, while adverse results could lead to substantial losses. Long-term investors may view any significant dips as potential buying opportunities, provided they believe in the company’s overall strategy and pipeline robustness.
In conclusion, while INmune Bio presents an intriguing opportunity within the biotech space, a balanced approach emphasizing risk management and consideration of trial outcomes is advisable. Monitoring upcoming presentations and closely following industry developments will be crucial in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.
Presentations:
| Title: | XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial |
| Date: | Monday, December 1, until Tuesday December 2, 2025 |
| Time: | 3:30pm (December 1 st ) – 5:30pm (December 2 nd ) PT |
| Location: | P057 |
| Presenting author: | Kim A. Staats, PhD. INmune Bio. |
| Title: | Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease |
| Date: | Thursday, December 4, 2025 |
| Time: | 7:15am - 5:00pm PT |
| Location: | P316 |
| Presenting author: | Sarah Barnum, PhD. Cognition Metrics. |
About INmune Bio Inc.
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target immunology and inflammation. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. The second program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. The third program, INKmune®, is designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
What are the key findings from the Phase 2 MINDFuL trial presented by INmune Bio Inc. (INMB) at the CTAD conference regarding XPro1595's effectiveness in treating early Alzheimer's disease?
How does INmune Bio Inc. (INMB) plan to leverage data from the Early Mild Alzheimer’s Cognitive Composite (EMACC) in conjunction with blood-based biomarkers for future clinical trials?
What are the potential implications for investors following INmune Bio Inc. (INMB)'s upcoming presentations at the CTAD conference regarding their product development timeline?
How does INmune Bio Inc. (INMB) intend to address the risks and uncertainties related to FDA approval for their drug candidates mentioned in the press release?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-4.53% G/L:
$1.58 Last:
313,312 Volume:
$1.66 Open:
